Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOVO ER: Insulin Aspart Protocol in Emergency Room
NCT00663624Phase 4Withdrawn
- Sponsor
- Emory University
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 4, randomised, open-label trial of insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Emory University. Primary endpoint: Hospital Length of Stay. Status: withdrawn.
02
Drugs
insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00663624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663624.